Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialDaniel V.T. Catenacci, David Cunningham, Salah‐Eddin Al‐Batran et al.|The Lancet Oncology|2017Cited by 347
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.David Cunningham, Daniel Virgil Thomas Catenacci, Niall C. Tebbutt et al.|Journal of Clinical Oncology|2015Cited by 144